

12<sup>th</sup> International Conference and Exhibition on **Pharmacovigilance & Drug Safety**  
&  
22<sup>nd</sup> International Conference and Exhibition on **Pharmaceutical Formulations**  
&  
21<sup>st</sup> Euro-Global Summit on **Toxicology and Applied Pharmacology**

July 04-06, 2019 Valencia, Spain

### **Risk and benefit profile of SGLT2 inhibitors in patients with diabetes mellitus**

**Anoop Kumar**  
NIPER, India

Recently, Food and Drug Administration (FDA) has approved sodium/glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, very less information is available. Thus, we have tried to find out the risk & benefit profile of SGLT 2 inhibitors. A total of 1,042 studies have been published from Nov. 2012-Nov.2017 regarding SGLT2 inhibitors. After inclusion and exclusion criteria, 27 studies have been selected for risk (17) and benefit (10) analysis. The results of the current study have shown the various therapeutic benefits of SGLT2 inhibitors. However, emerging evidence indicate various adverse drug reactions such as foot and toe amputation, cancer, diabetic ketoacidosis, bone fracture risk and urinary as well as mycotic genital infection. The causality assessment has shown a correlation between SGLT2 inhibitors and diabetic ketoacidosis and urinary tract infection.